Collegium Pharmaceutical, Inc.
COLL
$34.87
-$0.82-2.30%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 193.52M | 205.45M | 209.36M | 188.00M | 177.76M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 193.52M | 205.45M | 209.36M | 188.00M | 177.76M |
| Cost of Revenue | 20.80M | 21.60M | 21.66M | 22.19M | 21.48M |
| Gross Profit | 172.72M | 183.85M | 187.70M | 165.81M | 156.27M |
| SG&A Expenses | 86.35M | 66.67M | 65.55M | 72.70M | 76.42M |
| Depreciation & Amortization | 55.47M | 55.47M | 55.47M | 55.47M | 55.47M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 162.62M | 143.74M | 142.68M | 150.36M | 153.38M |
| Operating Income | 30.90M | 61.71M | 66.68M | 37.64M | 24.38M |
| Income Before Tax | 18.74M | 29.04M | 43.44M | 17.03M | 3.12M |
| Income Tax Expenses | 4.24M | 12.07M | 11.93M | 5.04M | 705.00K |
| Earnings from Continuing Operations | 14.50M | 16.96M | 31.51M | 11.98M | 2.42M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.50M | 16.96M | 31.51M | 11.98M | 2.42M |
| EBIT | 30.90M | 61.71M | 66.68M | 37.64M | 24.38M |
| EBITDA | 86.83M | 118.11M | 123.18M | 94.24M | 80.94M |
| EPS Basic | 0.45 | 0.54 | 1.00 | 0.38 | 0.08 |
| Normalized Basic EPS | 0.37 | 0.91 | 0.95 | 0.38 | 0.11 |
| EPS Diluted | 0.04 | 0.46 | 0.84 | 0.34 | 0.07 |
| Normalized Diluted EPS | 0.29 | 0.72 | 0.76 | 0.31 | 0.11 |
| Average Basic Shares Outstanding | 32.09M | 31.65M | 31.57M | 31.81M | 31.79M |
| Average Diluted Shares Outstanding | 40.07M | 40.08M | 39.44M | 39.08M | 32.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |